6 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 6 Phase 2, 3 Not applicable, 1 Early Phase 1, 1 Phase 1, 1 Phase 4.
Follow Hemangioblastoma: new trials by email Literature Review of Hemangioblastoma trials Research Report on Hemangioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Embolization for Highly Vascular Brain Tumors Preoperative Endovascular Embolization - Brain Neoplasms, Meningioma | Not applicable | Not yet recruiting | Assiut University | 55 | 2026-10-01 | 2026-09-17 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial Belzutifan - Von Hippel Lindau, Von Hippel Lindau Disease | Phase 2 | Recruiting | José Claudio Casali da Rocha | 100 | 2024-01-01 | 2025-09-11 |
| Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification Observational - Glioma, Glioneuronal Tumor | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 1650 | 2023-03-21 | 2025-12-17 | |
| Propranolol and Von Hippel-Lindau Disease Propranolol, follow-up - Hemangioblastoma of CNS, Von Hippel-Lindau Disease | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 85 | 2023-01-16 | 2023-12-13 |
| 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Ga68-DOTATATE-PET/MRI - CNS Tumors, Meningioma | Phase 4 | Recruiting | Weill Medical College of Cornell University | 200 | 2019-09-04 | 2025-11-21 |
| Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System evaluation of anxiety with psychosocial scales - Hemangioblastoma (HB) of the Central Nervous System (CNS) | Not applicable | Completed | Assistance Publique Hopitaux De Marseille | 42 | 2014-05-02 | 2023-04-06 |
| Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) Vorinostat - Von Hippel-Lindau Disease | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 7 | 2014-04-05 | 2018-09-14 |
| TKI 258 in Von Hippel-Lindau Syndrome (VHL) Dovitinib - Von Hippel-Lindau Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2012-11-01 | 2017-02-13 |
| Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease Avastin - Hemangioblastomas, Von Hippel Lindau Disease | Early Phase 1 | Terminated | Dartmouth-Hitchcock Medical Center | 1 | 2009-12-01 | 2012-05-11 |
| Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease 89Zr bevacizumab PET scan - Von Hippel-Lindau Disease, Hemangioblastoma | Completed | University Medical Center Groningen | 22 | 2009-09-01 | 2024-05-06 | |
| Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Sunitinib - CNS Cancer, Meningioma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 50 | 2007-10-01 | 2016-01-25 |
| Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow SU011248 - Von Hippel-Lindau Syndrome, Renal Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2006-05-01 | 2024-06-27 |
| Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 PTK787/ZK 222584 - Von Hippel-Lindau Disease, CNS Hemangioblastoma | Phase 2 | Completed | Novartis Pharmaceuticals | 11 | 2003-02-01 | 2017-03-06 |
| Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Hemangioblastoma, Hippel Lindau Disease | Active not recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 250 | 2001-02-15 | 2026-08-31 | |
| Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors Deafness, Kidney Diseases | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 75 | 1997-04-01 | 2008-03-04 |
von Hippel-Lindau Disease (10) · Carcinoma, Renal Cell (3) · Central Nervous System Neoplasms (3) · Meningioma (3) · Brain Neoplasms (2) · Cysts (2) · Neoplasms (2) · Neuroectodermal Tumors, Primitive (2) · Paraganglioma (2) · Pheochromocytoma (2) · Adenoma, Islet Cell (1) · Adrenal Gland Neoplasms (1) · Anus Neoplasms (1) · Biliary Tract Neoplasms (1)
Hemangioma (16) · Hemangioma, Capillary (16) · Neoplasms by Histologic Type (16) · Neoplasms, Vascular Tissue (16) · Nervous System Diseases (15) · Neoplasms (14) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Neurocutaneous Syndromes (11) · Abnormalities, Multiple (10) · Angiomatosis (10) · Cardiovascular Diseases (10) · Ciliopathies (10) · Congenital Abnormalities (10) · Neoplasms by Site (10)
Sunitinib (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Bevacizumab (1) · Nivolumab (1) · Propranolol (1) · Vorinostat (1) · Watchful Waiting (1) · belzutifan (1) · vatalanib (1)
National Institute of Neurological Disorders and Stroke (NINDS) (3) · M.D. Anderson Cancer Center (2) · Assistance Publique - Hôpitaux de Paris (1) · Assistance Publique Hopitaux De Marseille (1) · Assiut University (1) · Dartmouth-Hitchcock Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Instituto do Cancer do Estado de São Paulo (1) · José Claudio Casali da Rocha (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · University Medical Center Groningen (1) · Weill Medical College of Cornell University (1)
United States (9) · France (3) · Brazil (2) · Netherlands (2) · Austria (1) · Belgium (1) · Germany (1) · Greece (1) · Italy (1) · Norway (1) · Portugal (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Eric Jonasch, MD (2) · Prashant Chittiboina, M.D. (2) · Camila MV Moniz, Doctor (1) · J Marc Pipas, MD (1) · Jana Ivanidze, MD/Ph.D (1) · Michael Weller (1) · Philippe Metellus, MD (1) · Sjoukje Oosting, MD (1) · Thomas Kaley, MD (1)
PMID 22105611, PMID 24579662, PMID 34783716, PMID 35275019, PMID 35661809, PMID 37018064, PMID 38553990